Last reviewed · How we verify
NCT02041624: ALTO
An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.
trial in Allergic Rhinitis Due to Grass Pollens in 740 participants. Terminated before completion.
1 December 2015
Quick facts
| Lead sponsor | Stallergenes Greer |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 740 |
| Start date | 1 May 2014 |
| Primary completion | 1 December 2015 |
| Estimated completion | 1 December 2015 |
| Sites | 1 location across France |
Conditions studied
- Allergic Rhinitis Due to Grass Pollens — all drugs for Allergic Rhinitis Due to Grass Pollens →
Sponsor
Stallergenes Greer — full company profile →
Who can join
5 and older, any sex, with Allergic Rhinitis Due to Grass Pollens. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Health related quality of life
Time frame: patients will be followed for the duration of the treatment, an expected average of 6 months/year
The primary objective is to describe the patient's perception of the impact of ORALAIR® on his/her health related generic and disease specific quality of life during the grass-pollen season in real-life settings.
Sponsor's own description
The purpose of the present study is to describe patient's perception of quality of life and effectiveness of ORALAIR® over a follow-up period up to 5 years, in real-life settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02041624
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Stallergenes Greer trials
Trials by the same sponsor.
- NCT05668390 — Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma · Phase 3 · completed
- NCT06574061 — Evaluation of the Benefits of Sublingual AIT (PRACTIS) · completed
- NCT02443805 — Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR · Phase 3 · completed
- NCT04004351 — Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02041624 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stallergenes Greer
- Last refreshed: 15 April 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02041624.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing